Formulation Development
Nexcella Announces Patients Already Treated With CAR-T NXC-201; Estimates 100-Patient Total Enrollment for FDA Approval BLA Submission
Nexcella, Inc. recently announced 50 relapsed/refractory multiple myeloma patients have already been dosed with next-generation CAR-T NXC-201 in its ongoing Phase 1b/2a clinical trial. Nexcella…
Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. & Portfolio of Investigational Therapeutics
Rhythm Pharmaceuticals, Inc. recently announced Rhythm’s Netherlands subsidiary, Rhythm Pharmaceuticals Netherlands B.V., acquired Xinvento B.V., a Netherlands-based biotech company focused on developing therapies for congenital…
Redx & Jounce Announce Recommended Business Combination
Redx Pharma and Jounce Therapeutics, Inc. recently announce an unanimously recommended Business Combination of the two companies via a proposed all share merger transaction. Redx…
VBL Therapeutics & Notable Labs Announce Definitive Merger Agreement
VBL Therapeutics and Notable Labs, Inc. recently announced they have entered into a definitive merger agreement. The combined company will focus on the advancement of…
BriaCell Reports Positive Survival Data in Advanced Metastatic Breast Cancer
BriaCell Therapeutics Corp. recently reported updated survival data from its previously disclosed group of 12 patients (11 patients enrolled in 2021/2022) in the ongoing Phase…
Ocean Biomedical Celebrates Discovery of Bispecific Antibodies & Immune Checkpoint Inhibitors That Kill Glioblastoma Cells & Melanoma Cells & Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90%
Ocean Biomedical, Inc. celebrates the discovery of bispecific antibodies that target Chitinase 3-like-1 and immune checkpoint inhibitors, killing glioblastoma cells and melanoma cells, and blocking the metastasis of malignant….
Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea
Daré Bioscience, Inc. recently announced the start of a Phase 1 study evaluating its development program targeted at treating primary dysmenorrhea by delivering the active…
Cue Biopharma Enters Strategic Collaboration & Option Agreement With Ono Pharmaceutical
Cue Biopharma, Inc. recently announced a collaboration and option agreement with Ono Pharmaceutical Co., Ltd. for CUE-401, a bispecific protein designed to induce and expand regulatory….
Eterna Therapeutics Enters Option & License Agreement With Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
Eterna Therapeutics Inc. recently announced it has entered into an exclusive option and license agreement with Lineage Cell Therapeutics, Inc. for the development of novel induced…
Ajinomoto Bio-Pharma Services Successfully Develops Highly Functional Ancestral RNA Ligase
Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, recently announced the development of a new enzyme for double strand oligonucleotide formation with high….
uniQure Announces the European Commission Approval of the First Gene Therapy for Adults With Hemophilia B
uniQure N.V. recently announced its partner, global biotechnology leader CSL, has received conditional marketing authorization (CMA) from the European Commission for HEMGENIX (etranacogene dezaparvovec), the first…
Processa Pharmaceuticals Announces Prioritization on Development of Next-Generation Chemotherapies
Processa Pharmaceuticals, Inc. reiterates the strategic prioritization of its pipeline of proprietary oncology drugs, defined as Next-Generation Chemotherapies (NGCs). Previous studies with these….
Icosavax Granted FDA Fast Track Designation for RSV & hMPV Vaccine Candidate
Icosavax, Inc. recently announced the US FDA has granted Fast Track designation for IVX-A12, a bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP…
Kadimastem Submits IND Application for its Phase 2a Clinical Trial With AstroRx for the Treatment of ALS
Kadimastem Ltd recently has submitted an Investigational New Drug (IND) application to the US FDA for an approval for a multi-site Phase 2a clinical trial to test its lead neurological….
Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetings
Ocuphire Pharma, Inc. recently announced two presentations featuring efficacy and safety results from the company’s recently completed ZETA-1 Phase 2 trial of oral APX3330 in…
Frontera Therapeutics Doses First Patient in a Trial of Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa
Frontera Therapeutics recently announced it has dosed the first patient in a clinical trial of its gene therapy product, FT-002. FT-002 is being studied for…
Cytovation Announces First Patient Dosed in Phase 2a Study Investigating CyPep-1 Monotherapy in Advanced Melanoma Refractory to Checkpoint Inhibitors
Cytovation ASA recently announced the first patient has been dosed in its Phase 2a study investigating CyPep-1 monotherapy in patients with advanced melanoma refractory to…
First Subject Dosed in Small Pharma’s First-in-Human Phase 1 Clinical Trial
Phase 1 study will compare two routes of SPL028 administration; intravenous and intramuscular….
VYNE Therapeutics Announces Positive Results from Phase 1a Single & Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor
VYNE Therapeutics Inc. recently announced positive results from the Phase 1a portion of its Phase 1a/b clinical trial evaluating its novel BET inhibitor, VYN201, for vitiligo…..
Akari Therapeutics Announces Preclinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy
Akari Therapeutics, Plc recently announced updates on progress in the pre-clinical development program for long-acting PAS-nomacopan as a potential treatment for geographic atrophy (GA) secondary…
